Ocrelizumab
| 證據等級: L5 | 預測適應症: 5 個 |
目錄
Ocrelizumab: From Multiple Sclerosis to HER2 Positive Breast Carcinoma
One-Sentence Summary
Ocrelizumab is an anti-CD20 monoclonal antibody used to deplete B cells in autoimmune conditions such as multiple sclerosis. The TxGNN model predicts it may be effective for HER2 Positive Breast Carcinoma, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure knowledge-graph inference with no corroborating evidence.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Multiple sclerosis (inferred from the mechanistic rationale text embedded in this evidence pack; not present in the structured indication/license fields) |
| Predicted New Indication | HER2 positive breast carcinoma |
| TxGNN Prediction Score | 99.89% |
| Evidence Level | L5 |
| US Market Status | ✗ Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available in the structured fields of this evidence pack (original_moa is unpopulated). Based on the rationale text accompanying the predictions, ocrelizumab is an anti-CD20 monoclonal antibody that works by depleting B cells, and is clinically used for autoimmune diseases such as multiple sclerosis. This is an immune-modulating mechanism, not a cytotoxic or oncogene-targeted one.
No mechanistic pathway connects B-cell depletion to HER2-driven tumor growth, hormone-receptor signaling (PR-positive/negative subtypes), or the luminal A/B and normal breast-like molecular subtypes also listed among the top-5 predictions. The model’s own rationale text for all five candidates explicitly states this is an indirect knowledge-graph association lacking biological plausibility — the drug and disease co-occur in the graph without a demonstrated causal or mechanistic link.
A notable data-quality issue further weakens confidence: for the rank-4 candidate (“breast tumor luminal A or B”), 19 literature records were initially surfaced, but manual review shows these are false positives caused by keyword collision — they are papers on B-cell immunology, hepatitis B vaccines, and HLA-B allele typing, none of which relate to breast cancer. This suggests the underlying evidence-matching pipeline is prone to spurious “B” string matches and should be treated with caution across this drug’s candidate set.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
Currently no related literature available
Note: A separate, lower-ranked candidate (“breast tumor luminal A or B”) did surface 19 PubMed records, but on review these are false-positive keyword matches (B-cell biology, hepatitis B vaccine studies, HLA-B allele typing) rather than genuine drug–disease evidence, and are therefore not presented as supporting literature.
US Market Information
No marketing authorization records found. Per taiwan_regulatory, ocrelizumab currently has a market status of Not Marketed with 0 licenses on file.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale:
- The top-ranked prediction (HER2 positive breast carcinoma) has zero supporting clinical trials or literature, and the model’s own rationale explicitly flags the absence of biological plausibility for a CD20/B-cell-depletion mechanism driving HER2+ tumor growth.
- Apparent literature support found for a related candidate turned out to be a false-positive artifact of keyword matching, further undermining confidence in the current evidence pipeline for this drug.
- Critical safety data (TFDA warnings/contraindications) is flagged as a Blocking data gap (DG001), which alone prevents progression past initial safety screening.
To proceed, the following is needed:
- TFDA label warnings and contraindications (resolve DG001)
- Confirmed, sourced mechanism-of-action data (resolve DG002)
- Genuine preclinical or translational evidence linking B-cell depletion pathways to any of the five predicted breast cancer subtypes
- Re-run literature/evidence matching with disambiguated search terms to eliminate “B” keyword false positives
- Confirmation of regulatory/marketing status in target jurisdiction(s), since the drug is currently unmarketed per this evidence pack
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.